Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Financial Toxicity and Quality of Life in Patients Undergoing Stem-Cell Transplant Evaluation: A Single-Center Analysis.
Hussaini SMQ, Ren Y, Racioppi A, Lew MV, Bohannon L, Johnson E, Li Y, Thompson JC, Henshall B, Darby M, Choi T, Lopez RD, Sarantopoulos S, Gasparetto C, Long GD, Horwitz ME, Chao NJ, Zafar SY, Sung AD. Hussaini SMQ, et al. Among authors: gasparetto c. JCO Oncol Pract. 2024 Mar;20(3):351-360. doi: 10.1200/OP.23.00243. Epub 2023 Dec 21. JCO Oncol Pract. 2024. PMID: 38127876
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.
Ballas L, Ailawadhi S, Narang M, Gasparetto CJ, Lee HC, Hardin JW, Durie BGM, Toomey K, Omel J, Wagner LI, Abonour R, Terebelo HR, Joshi P, Yu E, Liu L, Rifkin RM, Jagannath S. Ballas L, et al. Among authors: gasparetto cj. Pract Radiat Oncol. 2024 Mar-Apr;14(2):e141-e149. doi: 10.1016/j.prro.2023.11.004. Epub 2023 Nov 19. Pract Radiat Oncol. 2024. PMID: 37984714
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM. Bahlis NJ, et al. Among authors: gasparetto c. Nat Med. 2023 Oct;29(10):2570-2576. doi: 10.1038/s41591-023-02589-w. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783970 Free PMC article. Clinical Trial.
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
Schiller GJ, Lipe BC, Bahlis NJ, Tuchman SA, Bensinger WI, Sutherland HJ, Lentzsch S, Baljevic M, White D, Kotb R, Chen CI, Rossi A, Biran N, LeBlanc R, Grosicki S, Martelli M, Gunsilius E, Špička I, Stevens DA, Facon T, Mesa MG, Zhang C, Van Domelen DR, Bentur OS, Gasparetto C. Schiller GJ, et al. Among authors: gasparetto c. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e286-e296.e4. doi: 10.1016/j.clml.2023.06.001. Epub 2023 Jun 5. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37393120 Free article.
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C, DiCioccio RA, Haykal T, McManigle WC, Li Z, Anand SM, Poe JC, Bracken SJ, Jia W, Alyea EP 3rd, Cardones AR, Choi T, Gasparetto C, Grunwald MR, Hennig T, Kang Y, Long GD, Lopez R, Martin M, Minor KK, Quinones VLP, Sung AD, Wiggins K, Chao NJ, Horwitz ME, Rizzieri DA, Sarantopoulos S. Lin C, et al. Among authors: gasparetto c. Transplant Cell Ther. 2023 Mar;29(3):179.e1-179.e10. doi: 10.1016/j.jtct.2022.12.015. Epub 2022 Dec 25. Transplant Cell Ther. 2023. PMID: 36577483 Free PMC article. Clinical Trial.
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
Lee HC, Ramasamy K, Weisel K, Abonour R, Hardin JW, Rifkin RM, Ailawadhi S, Terebelo HR, Durie BGM, Tang D, Joshi P, Liu L, Jou YM, Che M, Hernandez G, Narang M, Toomey K, Gasparetto C, Wagner LI, Jagannath S. Lee HC, et al. Among authors: gasparetto c. Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):112-122. doi: 10.1016/j.clml.2022.11.008. Epub 2022 Nov 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36567211 Free article.
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
Baljevic M, Gasparetto C, Schiller GJ, Tuchman SA, Callander NS, Lentzsch S, Monge J, Kotb R, Bahlis NJ, White D, Chen CI, Sutherland HJ, Madan S, LeBlanc R, Sebag M, Venner CP, Bensinger WI, Biran N, DeCastro A, Van Domelen DR, Zhang C, Shah JJ, Shacham S, Kauffman MG, Bentur OS, Lipe B. Baljevic M, et al. Among authors: gasparetto c. EJHaem. 2022 Sep 30;3(4):1270-1276. doi: 10.1002/jha2.572. eCollection 2022 Nov. EJHaem. 2022. PMID: 36467792 Free PMC article.
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.
Kang Y, Sundaramoorthy P, Gasparetto C, Feinberg D, Fan S, Long G, Sellars E, Garrett A, Tuchman SA, Reeves BN, Li Z, Liu B, Ogretmen B, Maines L, Ben-Yair VK, Smith C, Plasse T. Kang Y, et al. Among authors: gasparetto c. Ann Hematol. 2023 Feb;102(2):369-383. doi: 10.1007/s00277-022-05056-7. Epub 2022 Dec 3. Ann Hematol. 2023. PMID: 36460794 Clinical Trial.
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.
Bashir Q, Nishihori T, Pasquini MC, Martens MJ, Wu J, Alsina M, Anasetti C, Brunstein C, Dawson P, Efebera Y, Gasparetto C, Geller N, Giralt S, Hall AC, Koreth J, McCarthy P, Scott E, Stadtmauer EA, Vesole DH, Hari P. Bashir Q, et al. Among authors: gasparetto c. Transplant Cell Ther. 2023 Jun;29(6):358.e1-358.e7. doi: 10.1016/j.jtct.2022.07.007. Epub 2022 Jul 12. Transplant Cell Ther. 2023. PMID: 35840087 Clinical Trial.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC; DETERMINATION Investigators. Richardson PG, et al. Among authors: gasparetto c. N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35660812 Free PMC article. Clinical Trial.
161 results